Anemia is one of the many serious consequences of CKD that often goes unrecognized and undertreated, leaving patients with low quality of life and at risk for increased morbidity and mortality. For many years, the standard treatment for anemia in CKD has been erythropoiesis-stimulating agents (ESAs) with iron; however, the full correction of hemoglobin with ESAs has been called into question due to safety concerns. Fortunately, new insights into the pathophysiology of anemia have revealed novel treatment targets that may overcome the limitations associated with ESA use. Increased understanding of hepcidin and hypoxia-inducible factor (HIF) in anemia has led to the development of HIF-prolyl hydroxylase inhibitors (HIF-PHIs). These oral small molecules have demonstrated Hb correction with lower peak serum erythropoietin levels and good overall tolerability. HIF-PHIs are currently being investigated for the treatment of anemia in CKD, myelodysplastic syndromes (MDS) and other disease states.

This ACCME/ANCC/ACPE/AAPA-accredited symposium will provide expert insights into emerging therapies for anemia management in CKD and MDS. An interprofessional faculty panel will explore the latest clinical trial data for HIF-PHIs and discuss how these novel agents compare to ESAs, biosimilars and other therapies for anemia management.  

View All Speakers


John Glaspy, MD, MPH

Estelle, Abe, and Marjorie Sanders Endowed Chair in Cancer Research Jonsson Comprehensive Cancer Center Professor of Medicine University of California, Los Angeles (UCLA) David Geffen School of Medicine Los Angeles, California
View Full Bio

David Henry, MD

Clinical Professor of Medicine University of Pennsylvania School of Medicine Vice Chairman, Department of Medicine Division of Hematology/Oncology Pennsylvania Hospital Philadelphia, Pennsylvania
View Full Bio

Wendy St. Peter, PharmD, FASN, FCCP, FNKF

Professor College of Pharmacy University of Minnesota Minneapolis, Minneapolis
View Full Bio

Ajay Singh, MBBS, FRCP, MBA

Senior Associate Dean for Global and Continuing Education Director, Master in Medical Sciences in Clinical Investigation Program Harvard Medical School Boston, Massachusetts
View Full Bio

Jeffrey Berns, MD

Associate Chief of the Renal, Electrolyte, and Hypertension Division Professor of Medicine and Pediatrics Perelman School of Medicine University of Pennsylvania Philadelphia, Pennsylvania
View Full Bio


In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 2.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This knowledge-based activity is approved for 2.25 contact hour (.225 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-18-011-L01-P).

Nursing (ANCC)
This activity is designated for 2.25 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Physician Assistants (AAPA)
Creative Educational Concepts has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.



This activity is supported through an independent educational grant from AstraZeneca.